Anduril Employee Tender Offer Tests a $90 Billion Valuation

Anduril is opening a reported insider share sale that would value the defense technology company at roughly $90 billion. The Anduril employee tender offer gives eligible shareholders liquidity while testing whether private investors will support that valuation.

The proposed transaction is open to current and former employees across 16 countries, according to tender details reported by Bloomberg. It is scheduled to close on November 9. Axios reported that Anduril plans to make about $1.3 billion of employee shares available.

This is not a conventional funding round that places fresh capital on Anduril’s balance sheet. It is a secondary transaction, meaning investors purchase existing shares from employees or other insiders. That distinction creates the central tension: the deal offers real liquidity, but it does not subject Anduril to public-market price discovery.

Anduril’s earlier financing already established it as the most prominent member of the new defense technology cohort. The company was valued at $61 billion after raising $5 billion in May 2026. The tender would lift that benchmark by almost half within six months.

The comparison is no longer limited to startups such as Shield AI, Saronic, or Chaos Industries. At $90 billion, Anduril’s private valuation enters territory occupied by established defense contractors with public financial statements, diversified programs, and decades of production history.

The Anduril Employee Tender Offer Creates a New Price

The tender turns private investor enthusiasm into a direct, time-limited test of demand for Anduril shares.

The offer reportedly allows current and former employees to sell some of their holdings at a valuation near $90 billion. Its multinational scope matters because equity awards often become harder to manage as a private company expands overseas. Local securities rules, taxes, and settlement requirements can complicate even a voluntary share sale.

A tender offer gives the company more control than informal secondary trading. Anduril can determine who is eligible, how many shares each person can sell, and which buyers receive allocations. Those restrictions can reduce chaotic transactions and create a more consistent reference price.

The process also gives employees a path to convert part of their compensation into cash. Private-company equity can carry substantial paper value without offering an easy way to pay taxes, buy a home, or diversify savings. A structured tender addresses that problem without forcing an immediate initial public offering.

The reported November 9 closing date creates a firm decision point. Eligible sellers must decide whether to keep their exposure or realize some value now. Participating investors must decide whether Anduril’s recent growth justifies buying at a higher benchmark.

The size is important. A transaction involving approximately $1.3 billion in available shares would be more meaningful than a small secondary trade between a few investors. It would provide a broader, although still managed, indication of demand.

Yet the headline valuation does not mean Anduril itself will receive $1.3 billion. Secondary buyers generally pay selling shareholders, while the company may facilitate the transaction. That structure separates employee liquidity from corporate fundraising.

The valuation also does not mean every Anduril share can immediately be sold at the same price. Private shares lack the continuous trading and public order book available for listed stocks. Transfer restrictions, share classes, and negotiated terms can affect the practical value of individual holdings.

A successful tender would still establish an influential reference point. Future recruits could evaluate equity grants against it, investors could use it when pricing later transactions, and acquisition targets could compare their offers with it.

That makes the Anduril employee tender offer more than an employee benefit. It becomes part of the company’s capital strategy and a signal to the wider defense technology market.

Anduril has moved quickly through earlier benchmarks. An August 2024 financing valued the company at $14 billion. Its Series G financing raised $2.5 billion at a $30.5 billion valuation in June 2025.

The company then raised $5 billion at a $61 billion valuation in May 2026. The reported tender price would therefore extend a rapid sequence of valuation increases rather than introduce an isolated number.

Each earlier round also involved investors purchasing newly issued equity. The tender is different because its immediate purpose is liquidity. Investors are buying access to existing ownership, not simply financing another manufacturing facility or research program.

That difference strengthens the signal in one respect. Buyers cannot justify the entire purchase as necessary capital for future company growth. They must believe the acquired shares themselves offer an acceptable risk and return.

However, the managed format limits what the signal proves. Anduril and its advisers can restrict supply, select participants, and negotiate terms privately. A carefully constructed transaction can clear at a price that might not survive unrestricted public trading.

The tender therefore creates a new price, not a definitive market verdict. Understanding that distinction is essential before treating $90 billion as a settled measure of Anduril’s value.

Why Investors Are Paying More for Anduril Shares

Investors are pricing Anduril as a scaled technology manufacturer, not merely as another government contractor.

The company’s operating progress helps explain why buyers would consider the higher valuation. Anduril reported $2.2 billion in 2025 revenue, twice its previous annual result. It also said its workforce nearly doubled during that year.

The company raised its $5 billion Series H to support manufacturing capacity and research. That round valued Anduril at $61 billion, twice its June 2025 benchmark. Thrive Capital and Andreessen Horowitz led the financing.

Anduril’s products span autonomous aircraft, underwater vehicles, sensors, counter-drone systems, missiles, and command software. Lattice, its software platform, combines information from distributed sensors and helps operators coordinate connected systems.

This product range supports a larger argument about Anduril’s addressable market. The company is not relying on one drone or software subscription. It is trying to supply the software, hardware, and manufacturing capacity behind several military missions.

Recent contract activity gives investors evidence that government customers are willing to use that broader model. In March 2026, the U.S. Army consolidated 120 Anduril arrangements into a single enterprise agreement.

The Army agreement has a ceiling of $20 billion over as many as ten years. It covers software, integrated hardware, data infrastructure, computing resources, and related services.

A ceiling is not guaranteed revenue. It defines the maximum amount that agencies may order under the agreement. Actual sales depend on funded orders, performance, delivery schedules, and changing military requirements.

Still, the structure lowers purchasing friction. The Army can use pre-negotiated terms rather than creating a separate procurement vehicle for every requirement. For Anduril, that arrangement can shorten the path from customer demand to a funded order.

The company has also reached production and demonstration milestones beyond its original surveillance products. During 2025, Anduril said it delivered its first international program of record to the Royal Australian Navy.

A program of record is a formally funded government acquisition program, not an experimental pilot. That designation matters because defense startups often demonstrate impressive prototypes without converting them into sustained production.

Anduril also demonstrated autonomous flight under a U.S. Air Force unmanned combat aircraft program. The achievement places the company in a competition involving larger platforms, longer development cycles, and more demanding integration requirements.

The investment case therefore rests on two connected expectations. First, militaries will buy more autonomous systems and software-defined equipment. Second, Anduril can manufacture those systems at a pace associated with commercial technology companies.

Those expectations are reinforced by government interest in less expensive, more numerous weapons. Recent conflicts have shown the value of drones, distributed sensors, and systems that can operate without placing a person inside every platform.

Traditional defense contractors are responding to the same demand. Lockheed Martin, Northrop Grumman, RTX, Boeing, and General Dynamics retain deep relationships, classified infrastructure, manufacturing experience, and large installed programs.

Anduril’s advantage is supposed to come from speed and product ownership. It often develops systems before receiving a final government specification, then offers customers an existing product. That approach contrasts with programs built around detailed government requirements and reimbursed development costs.

The model can shorten development cycles, but it shifts more risk onto the company. Anduril must finance engineering and manufacturing before it knows how much a customer will ultimately order.

Large private financings make that strategy possible. They allow Anduril to build factories, acquire specialized companies, and retain engineers through lengthy procurement cycles. The tender can complement that strategy by making equity compensation more useful to employees.

This connection explains why the share sale matters beyond valuation headlines. Anduril needs specialized workers to develop software, integrate sensors, build aircraft, and navigate government programs. Private-company liquidity can help it compete for those workers without listing immediately.

Employee Liquidity Is Becoming an Alternative to an IPO

The tender reduces pressure to list now, while making Anduril’s eventual public-market test harder to avoid.

Fast-growing private companies face a recurring problem. Employees receive equity, but the value can remain inaccessible for years. New financing rounds create a headline price without guaranteeing that workers can sell at that price.

Regular tender offers can narrow that gap. They let employees diversify while the company keeps financial disclosures private and management retains greater control over timing. Investors gain access to a company that is otherwise difficult to buy.

For Anduril, that arrangement fits a period of aggressive expansion. A public listing would bring liquid shares and broader access to capital. It would also require detailed financial reporting, quarterly scrutiny, and continuous valuation by outside investors.

Founder Palmer Luckey has said an eventual IPO is certain and necessary if Anduril wants to compete for larger contracts. Anduril co-founder Trae Stephens previously described the company as having the shape of a publicly traded business.

Neither statement established a listing date. The employee tender gives Anduril room to delay that decision while addressing a practical reason employees might otherwise want an IPO.

The approach is not unique to defense technology. Large private technology companies increasingly use secondary sales to remain private after reaching a scale that once would have encouraged a listing.

These transactions serve several purposes at once. They reward long-serving employees, establish a reference price, admit new investors, and reduce internal pressure for a public exit.

However, they can also create uneven access. Employees may face limits on how much they can sell. Former workers can receive different terms, while tax treatment can vary across the 16 participating countries.

Investors may also receive information unavailable to employees or the public. Private transactions can involve confidential financial materials, shareholder agreements, and negotiated rights. That asymmetry makes the headline valuation less transparent than a stock exchange price.

The tender still represents a meaningful step toward public-company behavior. It requires organized shareholder communication, cross-border administration, legal review, and a process for matching substantial supply with institutional demand.

At $90 billion, the consequences of another repricing become larger. Equity grants based on the tender price could disappoint employees if a future financing or IPO occurs at a lower valuation. Acquisitions paid with shares would inherit the same valuation risk.

The offer also changes recruiting conversations. Candidates evaluating Anduril equity can point to a recent transaction involving real buyers. Yet they must still account for vesting schedules, transfer restrictions, dilution, and the absence of continuous liquidity.

Private-company valuations can rise in discrete steps because shares trade infrequently. Public stocks adjust every day as investors respond to earnings, budgets, execution problems, and broader market conditions.

That difference can work in Anduril’s favor while growth remains strong. It can also delay recognition of setbacks. A tender that attracts sufficient demand reveals that buyers accept the terms, but not how the wider market would price all outstanding shares.

The strongest interpretation is therefore narrower than the headline. The Anduril employee tender offer shows that selected investors are prepared to evaluate the company near $90 billion under controlled conditions.

It does not prove that public investors would sustain the same valuation after reviewing complete financial statements. That judgment requires evidence the tender cannot provide.

The $90 Billion Valuation Raises the Execution Bar

Anduril must convert contract access and technical demonstrations into repeatable production at a scale that supports its new valuation.

The first uncertainty concerns revenue quality. Defense contracts often announce large ceiling values, but agencies commit money through individual orders. The distance between an agreement’s maximum value and recognized revenue can be substantial.

Anduril’s $20 billion Army vehicle illustrates the issue. The agreement gives the company an efficient route to sell products and services. It does not require the Army to spend the entire ceiling.

Investors must assess how quickly orders arrive, what margins they produce, and how reliably Anduril delivers. Those details are harder to evaluate while the company remains private.

The second uncertainty is manufacturing. Software can be distributed quickly after development, but aircraft, missiles, sensors, and underwater vehicles require materials, factories, testing, and supply chains.

Anduril’s strategy depends on making complex defense systems in greater quantities and on shorter timelines. That goal requires capital, but capital alone does not remove production bottlenecks or certification requirements.

Failures also carry unusual consequences in defense. A consumer software bug might frustrate users. A malfunctioning autonomous aircraft can destroy costly equipment, delay a military program, and undermine confidence among government buyers.

Development programs expect setbacks, especially when they involve new aircraft or autonomy. The financial question is whether Anduril can correct those problems without losing schedules, contracts, or customer support.

The third uncertainty is valuation discipline. The reported $90 billion figure is almost three times Anduril’s June 2025 valuation. Revenue and contract activity have also grown, but the price embeds substantial future performance.

Public defense contractors offer a difficult comparison. They generally grow more slowly, yet they possess profitable programs, extensive backlogs, and decades of operating history. Investors can examine their cash flow, margins, debt, and program risks each quarter.

Anduril discloses far less. Its 2025 revenue provides a useful scale marker, but revenue alone cannot reveal profitability, cash consumption, contract concentration, or manufacturing economics.

The company’s Series H results included strong growth indicators. They did not provide the full financial detail that public investors normally use to judge a defense manufacturer.

That gap does not make the valuation wrong. Private investors can accept greater uncertainty because they expect faster growth. They may also receive contractual protections or access that ordinary public shareholders would not receive.

It does make the valuation harder to validate from outside. Readers should avoid dividing the headline value by one revenue figure and treating the result as a complete assessment. Contract duration, margins, capital needs, and dilution all matter.

Competition adds another layer. Palantir is an important software partner and a procurement reference point, but it also competes for defense data and command systems. Traditional contractors compete for aircraft, missiles, sensors, and integration work.

Startups including Shield AI and Saronic are pursuing overlapping autonomy and hardware opportunities. These companies remain smaller, yet they can pressure Anduril in focused markets and compete for engineers with defense experience.

Government procurement can also change quickly. Budgets move through political negotiations, program priorities shift, and contracts face protests or delays. International sales require separate approvals and can become entangled in foreign policy.

Ethical and regulatory debates surrounding autonomous weapons present another risk. Governments must determine acceptable levels of human control, testing, accountability, and compliance with the laws of armed conflict.

These concerns do not eliminate demand for autonomy. They affect deployment rules, customer adoption, and the time required to move from demonstration into operations.

A $90 billion valuation assumes Anduril can manage these challenges better than slower incumbents. That is the tradeoff behind the tender: investors gain exposure to unusually fast growth, but they accept unusually high execution expectations.

The transaction itself cannot settle that debate. It can only show whether enough investors are willing to make the trade at the offered terms.

Three Signals Will Test the Anduril Valuation Next

Tender participation, funded orders, and production delivery will determine whether the new benchmark reflects durable performance.

The first signal is the tender’s final demand. A completed offer near its reported size would indicate substantial investor interest and meaningful employee participation. A smaller allocation or changed terms would suggest the price required more careful management.

The result needs context. An oversubscribed offer can reflect genuine conviction, restricted share supply, or both. Investors should watch for the amount purchased, the final valuation, and any changes before the November 9 close.

Employee behavior will also be informative, although difficult to interpret. Heavy selling does not necessarily signal weak confidence. Workers may simply need diversification after years of holding concentrated private equity.

Limited selling would not automatically prove confidence either. Eligibility rules, tax costs, and restrictions can reduce participation. The clearest signal will come from the transaction’s final terms rather than speculation about individual motives.

The second signal is funded work under Anduril’s large government agreements. The Army vehicle provides a substantial opportunity, but purchase orders will reveal how quickly that opportunity becomes revenue.

Readers should distinguish contract ceilings from committed spending. New task orders, production quantities, and program funding offer stronger evidence than another maximum-value announcement.

International programs deserve similar attention. Delivery to the Royal Australian Navy established a useful precedent. Follow-on orders would show whether Anduril can turn one program into a repeatable export business.

The third signal is production performance. Anduril must deliver autonomous aircraft, missiles, sensors, and maritime systems at the speed assumed by its investment story. Factory announcements matter less than accepted products reaching customers on schedule.

The company’s manufacturing expansion makes this the most consequential operating test. Higher output with reliable quality would strengthen the $90 billion case. Delays, test failures, or rising costs would weaken it.

Those signals will shape the eventual IPO discussion. A successful tender can postpone a listing by giving employees liquidity. It cannot reproduce the transparency or continuous feedback of public markets.

An IPO would require Anduril to disclose how its revenue converts into cash, how much manufacturing consumes, and where major customer concentrations sit. Public investors would also compare its growth directly with established contractors and listed technology companies.

That comparison could reward Anduril if operating results match expectations. It could also compress the valuation if investors treat the company primarily as a capital-intensive manufacturer.

Until then, the private market controls the available evidence. Financing rounds establish negotiated benchmarks, while tenders provide occasional windows into investor demand.

The Anduril employee tender offer is valuable because it creates one of those windows. It connects a reported $90 billion valuation with a transaction involving real shares and willing sellers.

Yet the most important evidence will arrive after the tender closes. Contracted opportunities must become funded orders, production targets must become deliveries, and technical demonstrations must become dependable programs.

That is the standard Anduril has invited by approaching the value of established defense companies. The company is no longer being judged only on whether a startup can enter defense procurement.

It is being judged on whether a privately held technology company can become a full-scale defense prime without inheriting the delays and cost structures it set out to challenge.

Watch the final tender terms on November 9, then follow funded orders and delivery milestones rather than valuation headlines alone. Those results will show whether Anduril’s new share price reflects operating momentum or expectations running ahead of execution. For employees, the offer creates a rare chance to turn private equity into usable wealth. For investors, it creates exposure to a company reshaping defense procurement while assuming the risks of manufacturing at military scale. The next question is not whether buyers will accept the reported Anduril valuation once. It is whether contracts, production, and financial disclosure can support that valuation when a broader market eventually gets a vote.